Seprafilm cuts adhesions by 45%
This article was originally published in Clinica
Executive Summary
Genzyme's Seprafilm cut the incidence of surgical adhesions from 94% to 49% in a major study presented at the American College of Surgeons annual clinical congress (October 22nd-27th). The cleverly designed trial was described as a "landmark" by Dr Thomas Hunt during discussion of the paper, which was clearly the highlight of Tuesday afternoon's research session. David Firn reports from New Orleans.